PF4 Immunoassays Investigated in Vaccine-Induced Thrombotic Thrombocytopenia
By LabMedica International staff writers Posted on 07 Jun 2021 |
Image: The AcuStar Hemostasis Testing System (Photo courtesy of Werfen)
Post-vaccination embolic and thrombotic events, also termed vaccine-induced prothrombotic immune thrombocytopenia (VIPIT) or vaccine-induced immune thrombotic thrombocytopenia (VITT) are rare types of blood clotting events that were initially observed in a very small number of people who had previously received the COVID-19 vaccine.
Platelet factor 4 (PF4) is a small cytokine belonging to the CXC chemokine family that is also known as chemokine (C-X-C motif) ligand 4 (CXCL4). This chemokine is released from alpha-granules of activated platelets during platelet aggregation, and promotes blood coagulation by moderating the effects of heparin-like molecules. Due to these roles, it is predicted to play a role in wound repair and inflammation.
Medical Scientists at the Toulouse University Hospital (Toulouse, France) and their colleagues analyzed plasma samples from nine patients (median age, 44 years; seven females, two males) with suspected VITT after vaccination with ChAdOx1 nCoV-19 (AstraZeneca, Cambridge, UK). The most common events were cerebral vein thrombosis (n = 6) and splanchnic vein thrombosis (n = 5). All the patients had severe thrombocytopenia (median platelet count nadir, 29,000/mm3; range, 9 to 61,000) except for one woman with both cerebral vein thrombosis and splanchnic vein thrombosis.
Two rapid immunoassays widely used for the diagnosis of heparin-induced thrombocytopenia, STic Expert HIT (Stago Diagnostica, Asnières-sur-Seine, France) and HemosIL AcuStar HIT-IgG (Instrumentation Laboratory, Bedford, MA, USA) were performed on plasma samples to detect PF4-specific antibodies, and the results were negative in all the patients. Two other rapid tests had been performed in some patients by the referring laboratories and were negative, except in one patient, who had an equivocal result.
The team also tested all plasma samples with three different PF4-specific enzyme-linked immunosorbent assays, variable results were obtained. Significant levels of immunoglobulin (Ig)G antibodies to PF4 were detected in seven patients only by the assay that used PF4–poly(vinyl sulfonate) (PVS) complex as the antigenic target. In addition, optical density values were variable and lower than those previously reported with a similar test. The diagnosis of VITT was confirmed by PF4–serotonin release assay in all seven patients with IgG antibodies to PF4–PVS, whereas a standard serotonin release assay was negative in two patients.
The authors concluded that their results provide further support to show that rapid immunoassays should be avoided in the detection of PF4-specific antibodies in patients with suspected VITT. Therefore, the use of a sensitive, quantitative, immunologic test is strongly recommended, because according to the recently proposed algorithm, nonheparin anticoagulants should be preferred when clinically significant levels of anti-PF4 antibodies are detected. The study was published on May 19, 2021 in The New England Journal of Medicine.
Related Links:
Toulouse University Hospital
AstraZeneca
Stago Diagnostica
Instrumentation Laboratory
Platelet factor 4 (PF4) is a small cytokine belonging to the CXC chemokine family that is also known as chemokine (C-X-C motif) ligand 4 (CXCL4). This chemokine is released from alpha-granules of activated platelets during platelet aggregation, and promotes blood coagulation by moderating the effects of heparin-like molecules. Due to these roles, it is predicted to play a role in wound repair and inflammation.
Medical Scientists at the Toulouse University Hospital (Toulouse, France) and their colleagues analyzed plasma samples from nine patients (median age, 44 years; seven females, two males) with suspected VITT after vaccination with ChAdOx1 nCoV-19 (AstraZeneca, Cambridge, UK). The most common events were cerebral vein thrombosis (n = 6) and splanchnic vein thrombosis (n = 5). All the patients had severe thrombocytopenia (median platelet count nadir, 29,000/mm3; range, 9 to 61,000) except for one woman with both cerebral vein thrombosis and splanchnic vein thrombosis.
Two rapid immunoassays widely used for the diagnosis of heparin-induced thrombocytopenia, STic Expert HIT (Stago Diagnostica, Asnières-sur-Seine, France) and HemosIL AcuStar HIT-IgG (Instrumentation Laboratory, Bedford, MA, USA) were performed on plasma samples to detect PF4-specific antibodies, and the results were negative in all the patients. Two other rapid tests had been performed in some patients by the referring laboratories and were negative, except in one patient, who had an equivocal result.
The team also tested all plasma samples with three different PF4-specific enzyme-linked immunosorbent assays, variable results were obtained. Significant levels of immunoglobulin (Ig)G antibodies to PF4 were detected in seven patients only by the assay that used PF4–poly(vinyl sulfonate) (PVS) complex as the antigenic target. In addition, optical density values were variable and lower than those previously reported with a similar test. The diagnosis of VITT was confirmed by PF4–serotonin release assay in all seven patients with IgG antibodies to PF4–PVS, whereas a standard serotonin release assay was negative in two patients.
The authors concluded that their results provide further support to show that rapid immunoassays should be avoided in the detection of PF4-specific antibodies in patients with suspected VITT. Therefore, the use of a sensitive, quantitative, immunologic test is strongly recommended, because according to the recently proposed algorithm, nonheparin anticoagulants should be preferred when clinically significant levels of anti-PF4 antibodies are detected. The study was published on May 19, 2021 in The New England Journal of Medicine.
Related Links:
Toulouse University Hospital
AstraZeneca
Stago Diagnostica
Instrumentation Laboratory
Latest Hematology News
- Next Gen CBC and Sepsis Diagnostic System Targets Faster, Earlier, Easier Results
- Newly Discovered Blood Group System to Help Identify and Treat Rare Patients
- Blood Platelet Score Detects Previously Unmeasured Risk of Heart Attack and Stroke
- Automated Benchtop System to Bring Blood Testing To Anyone, Anywhere
- New Hematology Analyzers Deliver Combined ESR and CBC/DIFF Results in 60 Seconds
- Next Generation Instrument Screens for Hemoglobin Disorders in Newborns
- First 4-in-1 Nucleic Acid Test for Arbovirus Screening to Reduce Risk of Transfusion-Transmitted Infections
- POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy
- First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy
- Handheld White Blood Cell Tracker to Enable Rapid Testing For Infections
- Smart Palm-size Optofluidic Hematology Analyzer Enables POCT of Patients’ Blood Cells
- Automated Hematology Platform Offers High Throughput Analytical Performance
- New Tool Analyzes Blood Platelets Faster, Easily and Accurately
- First Rapid-Result Hematology Analyzer Reports Measures of Infection and Severity at POC
- Bleeding Risk Diagnostic Test to Reduce Preventable Complications in Hospitals
- True POC Hematology Analyzer with Direct Capillary Sampling Enhances Ease-of-Use and Testing Throughput